Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Want to see NEUP full AI Analyst Report?
Top Page
Neuphoria Therapeutics
(NASDAQ:NEUP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.00
▲(7.76% Upside)
Action:Reiterated
Date:06/03/26
The score is held back primarily by the sharply weakened TTM income statement (negative revenue and a very large net loss), partially offset by low leverage and currently positive cash flow. Technical indicators are broadly neutral, while valuation is constrained by negative earnings and no stated dividend. A recent milestone payment is a modest positive but remains uncertain and non-core.
Positive Factors
Low leverage
Neuphoria’s near-zero debt reduces solvency and refinancing risk, giving management durable financial flexibility to fund R&D, tolerate operating losses, or pursue partnerships without immediate reliance on external debt markets. This conservatism supports stability over the coming months.
Negative Factors
Large recent net loss
A very large trailing loss reflects operating-scale disconnect between revenue and expense; sustained heavy losses erode reserves, constrain reinvestment, and increase reliance on cash or capital markets. Over several months this magnifies execution and funding risk for clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Neuphoria’s near-zero debt reduces solvency and refinancing risk, giving management durable financial flexibility to fund R&D, tolerate operating losses, or pursue partnerships without immediate reliance on external debt markets. This conservatism supports stability over the coming months.
Read all positive factors
Neuphoria Therapeutics (NEUP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.27M
Dividend YieldN/A
Average Volume (3M)89.21K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,404,551
10 Day Avg. Volume91,705
30 Day Avg. Volume89,214
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.40
Price to Sales (P/S)0.74
P/FCF Ratio0.15
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue-0.89
Enterprise Value/Gross Profit-0.86
Enterprise Value/Ebitda-0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuphoria Therapeutics Business Overview & Revenue Model
Company Description
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with...
Neuphoria Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -10.47M | 15.65M | 0.00 | 0.00 | 383.16K | 0.00 |
| Gross Profit | -10.80M | 15.65M | -662.99K | -671.48K | 383.16K | 0.00 |
| EBITDA | -19.47M | -121.90K | -25.65M | -31.45M | -30.25M | -4.51M |
| Net Income | -27.55M | -369.63K | -23.19M | -32.18M | -31.62M | -6.53M |
Balance Sheet | ||||||
| Total Assets | 34.81M | 43.44M | 27.65M | 19.39M | 65.30M | 40.77M |
| Cash, Cash Equivalents and Short-Term Investments | 19.44M | 21.59M | 12.61M | 8.06M | 33.56M | 21.41M |
| Total Debt | 34.23K | 226.49K | 272.74K | 257.55K | 693.55K | 652.04K |
| Total Liabilities | 5.39M | 14.57M | 10.16M | 4.74M | 8.40M | 5.01M |
| Stockholders Equity | 29.42M | 28.87M | 17.49M | 14.65M | 56.91M | 35.76M |
Cash Flow | ||||||
| Free Cash Flow | 59.46M | 77.23M | -14.68M | -9.85M | -21.75M | -5.67M |
| Operating Cash Flow | 59.46M | 77.23M | -14.68M | -9.85M | -21.75M | -5.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 621.64K | -60.26K |
| Financing Cash Flow | 19.32M | 1.53B | 15.11M | 2.60M | 26.99M | 23.71M |
Neuphoria Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $21.07M | 142.25 | 0.27% | ― | 82.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $24.27M | -0.86 | -1538.29% | ― | ― | ― | |
47 Neutral | $79.17M | -0.58 | -258.45% | ― | ― | 33.42% | |
41 Neutral | $9.55M | -0.48 | -204.04% | ― | -59.95% | 56.67% | |
| ― | $12.52M | -0.62 | -94.79% | ― | ― | 79.70% |
* Healthcare Sector Average
NEUP
Neuphoria Therapeutics
4.37
-2.45
-35.92%
TXMD
TherapeuticsMD
2.20
1.03
88.03%
SINT
Sintx Technologies
2.12
-1.15
-35.17%
RNTX
Rein Therapeutics
0.96
-0.92
-49.10%
BIVI
BioVie
1.63
-9.77
-85.70%
BFRG
BullFrog AI Holdings, Inc.
0.62
-1.07
-63.43%
Neuphoria Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial
Positive
May 26, 2026
On May 21, 2026, Neuphoria Therapeutics received a revenue distribution payment of AUD $1.416 million tied to its historic role in the CTx CRC and the licensing of the KAT6 program to Pfizer, triggered by first dosing in a Phase III trial in ER+/H...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.